Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34(+) Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

SIMPLE SUMMARY: Epigenetic drugs, such as azacitidine (AZA), hold promise in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), however, the mechanisms predicting the patients’ response to AZA is not completely understood. Quiescence of hematopoietic CD34(+) progenito...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Koralkova, Pavla, Belickova, Monika, Kundrat, David, Dostalova Merkerova, Michaela, Krejcik, Zdenek, Szikszai, Katarina, Kaisrlikova, Monika, Vesela, Jitka, Vyhlidalova, Pavla, Stetka, Jan, Hlavackova, Alzbeta, Suttnar, Jiri, Flodr, Patrik, Stritesky, Jan, Jonasova, Anna, Cermak, Jaroslav, Divoky, Vladimir
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8125503/
https://ncbi.nlm.nih.gov/pubmed/33946220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados